Koers Jazz Pharmaceuticals, Inc. Nasdaq
Aandelen
US4721471070
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
|
10/07 | Jazz Pharmaceuticals plc bevordert Samantha Pearce tot Chief Commercial Officer | CI |
20/06 | JAZZ PHARMACEUTICALS PLC : Needham & Co. handhaaft koopadvies | ZM |
Omzet 2024 * | 4,05 mld. 3,72 mld. | Omzet 2025 * | 4,36 mld. 4 mld. | Marktkapitalisatie | 6,69 mld. 6,14 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 425 mln. 390 mln. | Nettowinst (verlies) 2025 * | 593 mln. 544 mln. | EV/omzet 2024 * | 2,44 x |
Nettoschuld 2024 * | 3,18 mld. 2,92 mld. | Nettoschuld 2025 * | 1,84 mld. 1,69 mld. | EV/omzet 2025 * | 1,96 x |
K/w-verhouding 2024 * |
18
x | K/w-verhouding 2025 * |
12,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,22% |
Recentste transcriptie over Jazz Pharmaceuticals, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 01-03-03 |
Renée Galá
PSD | President | 52 | 16-03-20 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 29-05-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 01-03-03 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-13 |
Patrick Enright
BRD | Director/Board Member | 62 | 01-01-09 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+61,53% | 856 mld. | |
+38,95% | 631 mld. | |
-3,66% | 359 mld. | |
+15,06% | 325 mld. | |
+9,18% | 297 mld. | |
+5,89% | 234 mld. | |
+16,53% | 226 mld. | |
+15,67% | 177 mld. | |
+2,47% | 165 mld. |
- Beurs
- Aandelen
- Koers JAZZ
- Koers